Cargando…

CK2 Inhibitor CX-4945 Blocks TGF-β1-Induced Epithelial-to-Mesenchymal Transition in A549 Human Lung Adenocarcinoma Cells

BACKGROUND: The epithelial-to-mesenchymal transition (EMT) is a major phenotype of cancer metastasis and invasion. As a druggable cancer target, the inhibition of protein kinase CK2 (formally named to casein kinase 2) has been suggested as a promising therapeutic strategy to treat EMT-controlled can...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Jiyeon, Hwan Kim, Seong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3762800/ https://www.ncbi.nlm.nih.gov/pubmed/24023938 http://dx.doi.org/10.1371/journal.pone.0074342

Ejemplares similares

Effects of the CK2 Inhibitors CX-4945 and CX-5011 on Drug-Resistant Cells
por: Zanin, Sofia, et al.
Publicado: (2012)

CX-4945 Induces Methuosis in Cholangiocarcinoma Cell Lines by a CK2-Independent Mechanism
por: Lertsuwan, Jomnarong, et al.
Publicado: (2018)

Phosphoproteomic Landscape of AML Cells Treated with the ATP-Competitive CK2 Inhibitor CX-4945
por: Rosales, Mauro, et al.
Publicado: (2021)

Structural Determinants of CX-4945 Derivatives as Protein Kinase CK2 Inhibitors: A Computational Study
por: Liu, Hongbo, et al.
Publicado: (2011)

Different Persistence of the Cellular Effects Promoted by Protein Kinase CK2 Inhibitors CX-4945 and TDB
por: Girardi, Cristina, et al.
Publicado: (2015)

Mechanistic Basis for In Vivo Therapeutic Efficacy of CK2 Inhibitor CX-4945 in Acute Myeloid Leukemia
por: Klink, Morgann, et al.
Publicado: (2021)

Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy – potential clinical relevance
por: D’Amore, Claudio, et al.
Publicado: (2020)

CX-4945: the protein kinase CK2 inhibitor and anti-cancer drug shows anti-fungal activity
por: Masłyk, Maciej, et al.
Publicado: (2017)

Validation of an LC–MS/MS Method for the Quantification of the CK2 Inhibitor Silmitasertib (CX-4945) in Human Plasma
por: Schwarz, Rico, et al.
Publicado: (2022)

Ginsenoside CK Inhibits TGF-β-Induced Epithelial-Mesenchymal Transition in A549 Cell via SIRT1
por: Sun, Mingyang, et al.
Publicado: (2021)

Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice
por: Ferrer-Font, Laura, et al.
Publicado: (2017)

The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies
por: Chon, Hae J., et al.
Publicado: (2015)

CX-4945 and siRNA-Mediated Knockdown of CK2 Improves Cisplatin Response in HPV(+) and HPV(−) HNSCC Cell Lines
por: Trembley, Janeen H., et al.
Publicado: (2021)

Identification of a Novel Function of CX-4945 as a Splicing Regulator
por: Kim, Hyeongki, et al.
Publicado: (2014)

A Novel Aminothiazole KY-05009 with Potential to Inhibit Traf2- and Nck-Interacting Kinase (TNIK) Attenuates TGF-β1-Mediated Epithelial-to-Mesenchymal Transition in Human Lung Adenocarcinoma A549 Cells
por: Kim, Jiyeon, et al.
Publicado: (2014)

Structural Basis for the Selective Inhibition of Cdc2-Like Kinases by CX-4945
por: Lee, Joo Youn, et al.
Publicado: (2019)

MEK Inhibitor PD-0325901 Overcomes Resistance to CK2 Inhibitor CX-4945 and Exhibits Anti-Tumor Activity in Head and Neck Cancer
por: Bian, Yansong, et al.
Publicado: (2015)

Correction: Lertsuwan et al. CX-4945 Induces Methuosis in Cholangiocarcinoma Cell Lines by a CK2-Independent Mechanism. Cancers 2018, 10, 283
por: Lertsuwan, Jomnarong, et al.
Publicado: (2022)

Silmitasertib (CX-4945), a Clinically Used CK2-Kinase Inhibitor with Additional Effects on GSK3β and DYRK1A Kinases: A Structural Perspective
por: Grygier, Przemyslaw, et al.
Publicado: (2023)

Up-regulation of Syndecan-4 contributes to TGF-β1-induced epithelial to mesenchymal transition in lung adenocarcinoma A549 cells
por: Toba-Ichihashi, Yoko, et al.
Publicado: (2015)

4,5,7‐Trisubstituted indeno[1,2‐b]indole inhibits CK2 activity in tumor cells equivalent to CX‐4945 and shows strong anti‐migratory effects
por: Birus, Robin, et al.
Publicado: (2021)

Gintonin Isolated from Ginseng Inhibits the Epithelial—Mesenchymal Transition Induced by TGF-β in A549 Lung Cancer Cells
por: Kim, Sung Jin, et al.
Publicado: (2023)

Preclinical In Vitro and In Vivo Evidence of an Antitumor Effect of CX-4945, a Casein Kinase II Inhibitor, in Cholangiocarcinoma()()()
por: Zakharia, Kais, et al.
Publicado: (2018)

Bufalin inhibits TGF-β-induced epithelial-to-mesenchymal transition and migration in human lung cancer A549 cells by downregulating TGF-β receptors
por: ZHAO, LEI, et al.
Publicado: (2015)

Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB
por: Buontempo, Francesca, et al.
Publicado: (2015)

Bleomycin (BLM) Induces Epithelial-to-Mesenchymal Transition in Cultured A549 Cells via the TGF-β/Smad Signaling Pathway
por: Chen, Kui-Jun, et al.
Publicado: (2016)

Effect of asiatic acid on epithelial-mesenchymal transition of human alveolar epithelium A549 cells induced by TGF-β1
por: Cui, Qingrong, et al.
Publicado: (2019)

Transtorming Growth Factor β1 Induces Epithelial-to-Mesenchymal Transition of A549 Cells
por: Kim, Ju Hee, et al.
Publicado: (2007)

Influence of Casein kinase II inhibitor CX-4945 on BCL6-mediated apoptotic signaling in B-ALL in vitro and in vivo
por: Richter, Anna, et al.
Publicado: (2020)

Inhibition of Casein Kinase II by CX-4945, But Not Yes-associated protein (YAP) by Verteporfin, Enhances the Antitumor Efficacy of Temozolomide in Glioblastoma
por: Liu, Xiangyu, et al.
Publicado: (2019)

Successful Partnerships: Exploring the Potential of Immunogenic Signals Triggered by TMZ, CX-4945, and Combined Treatment in GL261 Glioblastoma Cells
por: Villamañan, Lucía, et al.
Publicado: (2021)

Anti-adipogenic and Pro-lipolytic Effects on 3T3-L1 Preadipocytes by CX-4945, an Inhibitor of Casein Kinase 2
por: Yadav, Anil Kumar, et al.
Publicado: (2022)

Protein kinase CK2 activation is required for transforming growth factor β‐induced epithelial–mesenchymal transition
por: Kim, Seongrak, et al.
Publicado: (2018)

Repression of Smad4 by miR-205 moderates TGF-β-induced epithelial-mesenchymal transition in A549 cell lines
por: Zeng, Yuanyuan, et al.
Publicado: (2021)

Mechanisms of TGFβ-Induced Epithelial–Mesenchymal Transition
por: Moustakas, Aristidis, et al.
Publicado: (2016)

Combination Effect of Cilengitide with Erlotinib on TGF-β1-Induced Epithelial-to-Mesenchymal Transition in Human Non-Small Cell Lung Cancer Cells
por: Jeong, Jisu, et al.
Publicado: (2022)

The Epithelial-to-Mesenchymal Transition-Like Process Induced by TGF-β1 Enhances Rubella Virus Binding and Infection in A549 Cells via the Smad Pathway
por: Pham, Ngan Thi Kim, et al.
Publicado: (2021)

Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity
por: Quotti Tubi, Laura, et al.
Publicado: (2013)

Particulate Matter (PM(10)) Promotes Cell Invasion through Epithelial–Mesenchymal Transition (EMT) by TGF-β Activation in A549 Lung Cells
por: García-Cuellar, Claudia M., et al.
Publicado: (2021)

Formin-dependent TGF-β signaling for epithelial to mesenchymal transition
por: Rana, Manish K., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_439fp4te4jouh6abi0i2mak0td